1. Finland Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Biohit Oyj Class B

Biohit Oyj Class B

2.11
EUR
-0.08
(-3.65%)
Feb 17Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.25
0.31
0.42
0.56
0.61
0.67
0.67
0.47
0.62
0.73
0.87
0.94
1.04
- -
Basic EPS, GAAP
-0.43
-0.08
-0.2
-0.22
0.42
-0.14
-0.09
-0.22
-0.1
0.04
0.12
0.17
0.18
- -
Free Cash Flow per Basic Share
-0.36
-0.28
-0.24
-0.17
-0.08
-0.01
- -
- -
-0.03
0.12
0.04
0.01
-0.09
- -
Dividend per Share
0.73
0.72
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.63
0.9
0.72
0.73
1.16
1.06
0.97
0.58
0.49
0.5
0.62
0.8
0.98
0.74
Tangible Book Value per Share
1.5
0.78
0.62
0.65
0.7
0.73
0.74
0.46
0.48
0.49
0.61
0.77
0.94
0.65
Basic Weighted Avg Shares
14
14
14
15
15
15
15
15
15
15
15
15
15
14
Sales/Revenue/Turnover
3
4
6
8
9
10
10
7
9
11
13
14
16
- -
Operating Margin (%)
-169.7
-103.25
-58.83
-38.65
-18.11
-19.76
-14.04
-44.57
-16.03
10.31
13.96
17.9
20.39
- -
Depreciation Expense
- -
- -
- -
- -
2
2
2
2
2
- -
- -
- -
- -
- -
Net Income, GAAP
-6
-1
-3
-3
6
-2
-1
-3
-1
1
2
3
3
- -
Effective Tax Rate (%)
- -
- -
- -
- -
4.17
- -
- -
- -
- -
30.76
15.67
10.43
5.62
- -
Profit Margin (%)
-171.41
-26.61
-48.21
-40.21
68.37
-21.58
-14.1
-46.51
-16.02
5.49
14.16
17.98
17.4
- -
Working Capital
19
10
8
9
10
11
11
6
7
7
9
8
6
9
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
1
- -
Total Equity
22
13
10
11
17
16
15
9
7
7
9
12
15
11
Return on Invested Capital (%)
- -
- -
- -
- -
43.38
- -
- -
- -
- -
9.63
16.17
19.33
18.06
- -
Return on Capital (%)
- -
- -
- -
- -
43.78
- -
- -
- -
- -
10.06
21.17
22.58
18.98
- -
Return on Common Equity (%)
-20.42
-6.61
-25.38
-31.29
43.86
-12.93
-9.3
-28.46
-18.75
8.14
21.93
23.76
20.18
- -

Capital Structure

EUR

•

in mil. unless spec.
Sep'15
Dec'15
Jun'16
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
15
Market Capitalization
- -
- -
- -

Working Capital

EUR

•

in mil. unless spec.
Sep'15
Dec'15
Jun'16
Total Current Assets
10
9
11
Cash, Cash Equivalents & STI
8
7
8
Accounts Receivable, Net
1
1
2
Inventories
1
1
1
Total Current Liabilities
1
1
2
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.26%
12.86%
22.54%
Free Cash Flow
-87.28%
-71.72%
-840.76%
Net Income, GAAP
-24.98%
11.71%
6.62%
Sales/Revenue/Turnover
11.49%
17.44%
10.14%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
7
14
2025
- -
- -
16
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
0.09
0.17
2025
- -
- -
0.18
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jussi Hahtela
Full Time Employees
46
Sector
Health technology
Industry
Medical specialties
Address
Laippatie 1 Helsinki UU Finland 00880
IPO Date
Jun 18, 1999
Website
biohithealthcare.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Biohit Oyj, a Finnish biotechnology company founded in 1988 and headquartered in Helsinki, develops, manufactures and markets diagnostic tests, analysis systems, acetaldehyde-binding products and monoclonal antibodies for research institutions, healthcare facilities and industry worldwide; its core offerings include the GastroPanel test and quick test variant for assessing stomach mucosa conditions, atrophic gastritis and gastric cancer risks via blood samples, Helicobacter pylori quick tests, ColonView for detecting hidden intestinal bleeding and colorectal cancer risk, Acetium capsules and lozenges to neutralize carcinogenic acetaldehyde for gastric protection and smoking cessation aid, the patented FAEX sample collection tube for stool analysis, and point-of-care quick tests such as GastroPanel Quick Test NT; operations span Europe, Asia, South America and beyond through subsidiaries in Italy and the United Kingdom, with Series B shares listed on Nasdaq Helsinki under BIOBV. The company reports under a single diagnostics segment, targeting early detection and prevention of gastrointestinal diseases with 98.5% of 2024 revenue from international exports. Recent developments encompass securing European distribution rights for Biomedal’s gluten tests, launching the patented FAEX sample tube for internal ColonView use and external sales, completing clinical validation of GastroPanel Quick Test in India, confirming GastroPanel accuracy via Homerton University Hospital study in the UK, and signing a letter of intent with Singapore’s Restalyst in early 2025 for synergistic gastric cancer testing and new sales channels, alongside revenue growth to EUR 14.3 million and operating profit of EUR 2.6 million in 2024.